Combining Deep Learning and Handcrafted Radiomics for Classification of Suspicious Lesions on Contrast-enhanced Mammograms.

Journal: Radiology
Published Date:

Abstract

Background Handcrafted radiomics and deep learning (DL) models individually achieve good performance in lesion classification (benign vs malignant) on contrast-enhanced mammography (CEM) images. Purpose To develop a comprehensive machine learning tool able to fully automatically identify, segment, and classify breast lesions on the basis of CEM images in recall patients. Materials and Methods CEM images and clinical data were retrospectively collected between 2013 and 2018 for 1601 recall patients at Maastricht UMC+ and 283 patients at Gustave Roussy Institute for external validation. Lesions with a known status (malignant or benign) were delineated by a research assistant overseen by an expert breast radiologist. Preprocessed low-energy and recombined images were used to train a DL model for automatic lesion identification, segmentation, and classification. A handcrafted radiomics model was also trained to classify both human- and DL-segmented lesions. Sensitivity for identification and the area under the receiver operating characteristic curve (AUC) for classification were compared between individual and combined models at the image and patient levels. Results After the exclusion of patients without suspicious lesions, the total number of patients included in the training, test, and validation data sets were 850 (mean age, 63 years ± 8 [SD]), 212 (62 years ± 8), and 279 (55 years ± 12), respectively. In the external data set, lesion identification sensitivity was 90% and 99% at the image and patient level, respectively, and the mean Dice coefficient was 0.71 and 0.80 at the image and patient level, respectively. Using manual segmentations, the combined DL and handcrafted radiomics classification model achieved the highest AUC (0.88 [95% CI: 0.86, 0.91]) ( < .05 except compared with DL, handcrafted radiomics, and clinical features model, where = .90). Using DL-generated segmentations, the combined DL and handcrafted radiomics model showed the highest AUC (0.95 [95% CI: 0.94, 0.96]) ( < .05). Conclusion The DL model accurately identified and delineated suspicious lesions on CEM images, and the combined output of the DL and handcrafted radiomics models achieved good diagnostic performance. © RSNA, 2023 . See also the editorial by Bahl and Do in this issue.

Authors

  • Manon P L Beuque
    The D-Lab & The M-Lab, Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Marc B I Lobbes
    From the Department of Precision Medicine (M.P.L.B., Y.v.W., Y.W., S.P., H.C.W., P.L.) and Department of Radiology and Nuclear Medicine (M.B.I.L.), GROW School for Oncology and Reproduction, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands (M.B.I.L., H.C.W., P.L.); Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, the Netherlands (M.B.I.L.); Department of Imaging, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France (M.M., C.B.); and Biomaps, UMR1281 INSERM, CEA, CNRS, Université Paris-Saclay, Villejuif, France (C.B.).
  • Yvonka van Wijk
    From the Department of Precision Medicine (M.P.L.B., Y.v.W., Y.W., S.P., H.C.W., P.L.) and Department of Radiology and Nuclear Medicine (M.B.I.L.), GROW School for Oncology and Reproduction, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands (M.B.I.L., H.C.W., P.L.); Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, the Netherlands (M.B.I.L.); Department of Imaging, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France (M.M., C.B.); and Biomaps, UMR1281 INSERM, CEA, CNRS, Université Paris-Saclay, Villejuif, France (C.B.).
  • Yousif Widaatalla
    From the Department of Precision Medicine (M.P.L.B., Y.v.W., Y.W., S.P., H.C.W., P.L.) and Department of Radiology and Nuclear Medicine (M.B.I.L.), GROW School for Oncology and Reproduction, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands (M.B.I.L., H.C.W., P.L.); Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, the Netherlands (M.B.I.L.); Department of Imaging, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France (M.M., C.B.); and Biomaps, UMR1281 INSERM, CEA, CNRS, Université Paris-Saclay, Villejuif, France (C.B.).
  • Sergey Primakov
    The D-Lab: Decision Support for Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht.
  • Michael Majer
    From the Department of Precision Medicine (M.P.L.B., Y.v.W., Y.W., S.P., H.C.W., P.L.) and Department of Radiology and Nuclear Medicine (M.B.I.L.), GROW School for Oncology and Reproduction, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands (M.B.I.L., H.C.W., P.L.); Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, the Netherlands (M.B.I.L.); Department of Imaging, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France (M.M., C.B.); and Biomaps, UMR1281 INSERM, CEA, CNRS, Université Paris-Saclay, Villejuif, France (C.B.).
  • Corinne Balleyguier
    Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris-Saclay, Paris, France.
  • Henry C Woodruff
    The D-Lab, Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
  • Philippe Lambin
    Department of Radiation Oncology (MAASTRO Clinic), Dr. Tanslaan 12, Maastricht, The Netherlands.